Type in a keyword and see the report right away. Explore your online world!
If you have already a Newsmeter account:
You can free sign up for Newsmeter:
x
Alexandra Dreyfuss, MD, MS, weighs bridging vs consolidative radiotherapy strategies around CAR T-cell infusion in myeloma.
Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in relapsed multiple myeloma.
Luis E. Raez, MD, of Miami Cancer Institute, and Wade T. Iams, MD, of Tennessee Oncology, consider how to interpret descriptive comparisons between COPERNICUS and MARIPOSA, given median follow-up of 4.9 vs 22 months and no formal statistical testing.
Please enable Javascript In the newest episode of RadOnc on the Run, host Brandon Mancini, MD,...
Explore how menin inhibitors are managed in leukemia care, including key drug interactions, dosing adjustments, and realistic response timelines for patients.
Learn how clinicians recognize and manage drug-related differentiation syndrome, QTc prolongation, and dosing considerations when starting revimumab or ziftomainib in practice.
A panelist describes how the treating center, local oncologist, patient, and caregivers share responsibility for monitoring after CAR T-cell therapy, including warning symptoms, immune monitoring, and infection prevention.
The moderator reviews a guideline recommendation on CAR T-cell therapy and T-cell engagers at first relapse, and one panelist describes how it compares with their practice, including the rationale for sequencing and the questions that remain open.
Panelists discuss which patients at first relapse make them think of CAR T-cell therapy and which make them pause, including disease burden and the role of holding and bridging therapy, age and fitness, kidney function, and caregiver availability.
Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.
Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.
Sedhom traced his approach to mentorship from Thomas Smith, MD, during his oncology fellowship at...
'We thought there might be a preventive effect towards the development from CHIP to CCUS to MDS, so it’s a sort of a continuum,' said Kirsten Grønbæk, MD, PhD.
Ralph V. Boccia, MD, FACP, discusses payer models, prior authorization, cost recovery, and patient assistance for bispecifics like teclistamab/daratumumab.
